Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 2,292 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Follow-Up Questions
BCHMF 주식의 가격 성능은 어떻습니까?
BCHMF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Bachem Holding AG의 주요 사업 주제나 업종은 무엇입니까?
Bachem Holding AG은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
Bachem Holding AG의 시가총액은 얼마입니까?
Bachem Holding AG의 현재 시가총액은 $0입니다
Bachem Holding AG는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 11명의 분석가가 Bachem Holding AG에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 8명의 매수, 5명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다